This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fielding, R. M.
Right arrow Articles by Horner, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fielding, R. M.
Right arrow Articles by Horner, M. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 1999, p. 503-509, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Pharmacokinetics and Urinary Excretion of Amikacin in Low-Clearance Unilamellar Liposomes after a Single or Repeated Intravenous Administration in the Rhesus Monkey

Robert M. Fielding,1,* Lotus Moon-Mcdermott,1 Ramilla O. Lewis,1 and Michelle J. Horner2

NeXstar Pharmaceuticals, Inc., Boulder, Colorado,1 and Sierra Biomedical, Inc. Sparks, Nevada2

Received 4 May 1998/Returned for modification 23 August 1998/Accepted 1 December 1998

Liposomal aminoglycosides have been shown to have activity against intracellular infections, such as those caused by Mycobacterium avium. Amikacin in small, low-clearance liposomes (MiKasome) also has curative and prophylactic efficacies against Pseudomonas aeruginosa and Klebsiella pneumoniae. To develop appropriate dosing regimens for low-clearance liposomal amikacin, we studied the pharmacokinetics of liposomal amikacin in plasma, the level of exposure of plasma to free amikacin, and urinary excretion of amikacin after the administration of single-dose (20 mg/kg of body weight) and repeated-dose (20 mg/kg eight times at 48-h intervals) regimens in rhesus monkeys. The clearance of liposomal amikacin (single-dose regimen, 0.023 ± 0.003 ml min-1 kg-1; repeated-dose regimen, 0.014 ± 0.001 ml min-1 kg-1) was over 100-fold lower than the creatinine clearance (an estimate of conventional amikacin clearance). Half-lives in plasma were longer than those reported for other amikacin formulations and declined during the elimination phase following administration of the last dose (from 81.7 ± 27 to 30.5 ± 5 h). Peak and trough (48 h) levels after repeated dosing reached 728 ± 72 and 418 ± 60 µg/ml, respectively. The levels in plasma remained >180 µg/ml for 6 days after the administration of the last dose. The free amikacin concentration in plasma never exceeded 17.4 ± 1 µg/ml and fell rapidly (half-life, 1.47 to 1.85 h) after the administration of each dose of liposomal amikacin. This and the low volume of distribution (45 ml/kg) indicate that the amikacin in plasma largely remained sequestered in long-circulating liposomes. Less than half the amikacin was recovered in the urine, suggesting that the level of renal exposure to filtered free amikacin was reduced, possibly as a result of intracellular uptake or the metabolism of liposomal amikacin. Thus, low-clearance liposomal amikacin could be administered at prolonged (2- to 7-day) intervals to achieve high levels of exposure to liposomal amikacin with minimal exposure to free amikacin.

* Corresponding author. Present address: Biologistic Services, 498 Skytrail Rd., Boulder, CO 80302. Phone: (303) 786-7243. Fax: (303) 786-7243. E-mail: biopharm{at}worldnet.att.net.

Antimicrobial Agents and Chemotherapy, March 1999, p. 503-509, Vol. 43, No. 3
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Banerjee, S., Ghosh, J., Sen, S., Guha, R., Dhar, R., Ghosh, M., Datta, S., Raychaudhury, B., Naskar, K., Haldar, A. K., Lal, C. S., Pandey, K., Das, V. N. R., Das, P., Roy, S. (2009). Designing Therapies against Experimental Visceral Leishmaniasis by Modulating the Membrane Fluidity of Antigen-Presenting Cells. Infect. Immun. 77: 2330-2342 [Abstract] [Full Text]  
  • Sakai, H., Masada, Y., Horinouchi, H., Ikeda, E., Sou, K., Takeoka, S., Suematsu, M., Takaori, M., Kobayashi, K., Tsuchida, E. (2004). Physiological Capacity of the Reticuloendothelial System for the Degradation of Hemoglobin Vesicles (Artificial Oxygen Carriers) after Massive Intravenous Doses by Daily Repeated Infusions for 14 Days. J. Pharmacol. Exp. Ther. 311: 874-884 [Abstract] [Full Text]  
  • Desjardins, J., Emerson, D. L., Colagiovanni, D. B., Abbott, E., Brown, E. N., Drolet, D. W. (2004). Pharmacokinetics, Safety, and Efficacy of a Liposome Encapsulated Thymidylate Synthase Inhibitor, OSI-7904L [(S)-2-[5-[(1,2-Dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric Acid] in Mice. J. Pharmacol. Exp. Ther. 309: 894-902 [Abstract] [Full Text]  
  • Marier, J.-F., Lavigne, J., Ducharme, M. P. (2002). Pharmacokinetics and Efficacies of Liposomal and Conventional Formulations of Tobramycin after Intratracheal Administration in Rats with Pulmonary Burkholderia cepacia Infection. Antimicrob. Agents Chemother. 46: 3776-3781 [Abstract] [Full Text]  
  • Dhillon, J., Fielding, R., Adler-Moore, J., Goodall, R. L., Mitchison, D. (2001). The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother 48: 869-876 [Abstract] [Full Text]  
  • Schiffelers, R., Storm, G., Bakker-Woudenberg, I. (2001). Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48: 333-344 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»